Abstract. Volume reduction of the hippocampus observed with MRI is one of the most consistently described structural abnormalities in patients with schizophrenia. However, the timing, the association with treatment, and an intuitive explanation of morphologic changes are not known. This study analyzed subtle changes of the hippocampal structure in schizophrenics as compared to matched controls. The effect of age, duration of illness and treatment effects to local shape changes was studied with a new shape representation technique and an exploratory statistical analysis. Shape representation was based on a sampled medial model (M-rep) describing each shape by an 8 by 3 mesh with local position and width at each node. This model allows an independent analysis of shape deformation and of local atrophy. The exploratory statistical model was a repeated measures ANOVA, cast as a general linear multivariate model. The new procedure overcomes the problem of testing a very large number of correlated observations, which is a significant limitation of many other shape discrimination schemes. As a novel contribution not shown before, it models shape in combination with patient variables to answer important clinical questions in regard to drug response and longitudinal change in order to assess developmental and degenerative processes. The exploratory nature of the analysis means that our results must be replicated in a hypothesis driven independent patient study in order to provide full confidence in the conclusions.
Introduction
Schizophrenia is often subject to conflicting hypotheses about the cause and temporal evolution of the neuropathologic features of the disorder and its relationship to treatment. Volume reduction of the hippocampus is one of the most consistently described structural abnormalities in patients with schizophrenia.
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However, the cause and timing of this pathomorphologic feature of the illness is not known. Csernansky et al. [1, 2] suggests that a full characterization of neuroanatomical abnormalities will increase our understanding of etiology, pathogenesis, and pathophysiology of schizophrenia. Results show that the analysis of hippocampal shape discriminates schizophrenia and control subjects with greater power than volumetry [3, 4, 2] . Most recently, Shenton et al. [5] found that hippocampal volume and shape provided much better discrimination than each of these variables alone. All these studies suggest a clear need for studying shape rather than gross volume and for providing quantitative measures that are not only statistically significant but also neuroanatomically meaningful and intuitive.
The effects of drug treatment have been an issue that has complicated the interpretation of studies of neuropathology and brain morphology in schizophrenia. Most significant for patient outcome, however, is the question if certain drug treatment might prevent or delay loss of structure such as atrophy of hippocampus. A structure description based on medial object models, as used here, captures global object shape by the shape of its set of medial manifolds and local object properties by local width (radius) measurements. Such a description might have advantages over conventional surface-based or high-dimensional voxel deformation based descriptions [6, 7] . Medial manifold descriptions potentially provide us with natural and intuitive measurements such as global length, width as well as local thickness and bending [8] .
In the hippocampal shape analysis study presented here, we not only ask the scientific question if schizophrenics and controls differ in hippocampal shape but try to link quantitative morphologic measurements to treatment drug type and to longitudinal change with age or duration of illness. In this novel concept, both patient variables and shape parameters are becoming part of the statistical model.
Methods

Data, Subjects, Segmentation, Shape Model
Subjects The patient study is cross-sectional in design [9] and assesses potential differences in the hippocampus structure between patients in the first few years of illness versus patients who have been chronically ill. Early illness (age 16-30, N=34) and chronic (age 31-60, N=22) patients have been matched to a young and an older control group (N=26). Patients were characterized with regards to duration of illness and illness severity utilizing PANSS assessments. All patients and comparison subjects were right-handed male. At the time of the scan, 22 patients were on typical antipsychotic medication (haloperidol), and 35 were on atypical antipsychotic medications (olanzapine, risperidone).
Imaging and Segmentation
Patients were scanned on a GE Sigma Advantage MR system operating at 1.5 Tesla. The series used for this study was acquired as a 3D IR Prepped Fast SPGR, FOV=24cm; 256 256, 124 slices with 1.5 mm thickness. Analysis of the hippocampus was utilized a software package for threedimensional segmentation IRIS (free download at midag.cs.unc.edu). Hippocampal segmentation was based on a well-documented protocol and included the hippocampus proper, the subiculum, the fimbria, and subsplenial gyrus. All measurements were completed by a single rater (S.A.S.) whose intrarater reliability was 0.86 for the left hippocampus and 0.88 for the right hippocampus.
Shape Representation We used a shape analysis pipeline to parametrize the surface of each object, to provide an area preserving mapping to a sphere with uniform sampling, and to calculate the minimal M-rep sampling necessary given an error criterion for object overlap and mean absolute boundary distance. Shapes were aligned using Procrustes fit at the boundary but we did not include normalization for size since the analysis as used herein naturally separates scale. These procedures have been described elsewhere [6] and will not be discussed here. The final M-rep representation for the population of 79 left and right hippocampal shape was determined as a 3x8 grid of mesh points (see Fig. 1 . A simplified M-rep representation with {x, y, z} and radius for each of the 24 mesh nodes was used.
Statistical Model
Data Structure Data were reduced to two outcome measures: Euclidean distance in mm from some common origin across all hippocampi was the first outcome of interest. This metric reduces the {x, y, z}-tuple to a single distance and avoids to model interrelationships among x, y and z and their variances. We are aware of possible limitations of this data reduction approach and are currently exploring alternative shape representation schemes. Radius in mm of each sphere (24 spheres per hippocampus) was the second outcome of interest. Each outcome was analyzed completely separately from the other. For each analysis, the within subject effects included Side (of brain), Row, and Column (in M-rep structure). Each of the two Y matrices are 79 x 48, with 79 subjects and 24 M-rep points per side of the hippocampus (Left and Right). Predictors for within subject effects in the model model were: Side, Row, Column, Side x Row, Side x Column, Row x Column, and Side x Row x Column (10+21+14 parameters). Predictors for between subject effects in the model model were: Age (years), Drug Type (none, typical, or atypical), Drug Type x Age (2 parameters) interaction, and Drug Type x Duration (8 parameters).
Model Reduction Analysis began with a residual analysis conducted on the full model on both outcomes of interest. The approach followed recommendations as found in [10] . The model reduction follows a planned, fixed sequence of tests, always from a larger to smaller model ( [11, 12] ). The exploratory analysis requires us to report all steps of our process to avoid misleading interpretation of the results. The multiple steps for selecting the optimal models are shown in the Appendix 4 with the example of the deformation model.
Results
The results of this exploratory analysis scheme must be interpreted with caution due to the large number of data-driven features. A novel contributions not shown before in clinical studies, we seperateley tested for differences in local width and local deformation, and modelled shape in combination with patient variables. It is important to emphasize that both measures, the Euclidean Distance and the Radius Distance, are differential measures. Shapes are normalized by average distance from origin and average radius. The measures thus represent pure shape deformation and pure radius deformation measures after normalization. This type of shape analysis is different from an analysis of objects of different size and asking for the location of major size differences, although this question could be explored using a similar analysis scheme.
Global size differences Our shape modelling scheme allows us to infer global volume indirectly via M-rep radius using the statistical analysis framework presented here. The integrated radius measure serves as an indicator of global size. Ongoing research will replace this strong simplification by surface/volume fractional representation per medial node using differential geometry methods. The global hippocampal volume, obtained by averaging the m-rep radius feature (Log2(Radius)) over Side, Row and Column, was put into the exploratory analysis scheme (4). The final model included Age, Drug Type(Atyp, Typ, Cntl), Drug(yes, no)*Age and Drug(yes, no)*Duration as predictors. The volume difference between Typical and Control, and between Atypical and Control are not significant, but the hippocampal volumes of the Atypical and Typical groups show a significant difference (p < 0.0234).
Euclidean Distance Results
The final model for distance included Age, Drug (yes, no), and Age x Drug as predictors, with distance averaged across side of the hippocampus (left/right) as the outcome of interest. The difference in hippocampus shape between patients and controls as measured by M-rep distance is represented by Fig. 2. Figures left to right represent the difference at age 20, 30 and 40, respectively. The difference in hippocampus shape deformation between patients and controls is located mostly in the tails of the hippocampus, and becomes more pronounced over time. Figure 4 left represents the change in hippocampus shape over ten years for a control and demonstrates a very small longitudinal deformation change.
Age 20
Age 30 Age 40 Comparison: Longitudinal shape change of Controls Figure 4 illustrates the change in hippocampus shape and local width over ten years for controls using the final models for Deformation (left) and Radius (right). The vertical axis represents deformation in mm and a difference of differences, namely Control (Left-Right) -Control(Left-Right), respectively. Both figures demonstrate the very small changes for controls over the 10 years interval.
Discussion
We present a statistical analysis of anatomical shape integrated into a statistical framework that includes patient variables. Treating shape, age, and drug treatment as variables in a statistical model is new and has not been shown before. This analysis will potentially lead to answers in regard to progression of shape change with different drug treatments or with neurodegeneration, both highly relevant for Psychiatry research. The global Volume differences between Typical and Control, and also between Atypical and Control, are not significant. The hippocampal volumes of the Atypical and Typical groups, however, show a significant difference. The Typical group shows smaller hippocampal volume than the Atypical group. The Deformation measure shows a significant shape change between controls and schizophrenics, but not for subgroups treated with different drugs and not for side (left,right). This deformation confirms an earlier shape analysis of the same shapes using spherical harmonics and point distribution models [8] . The tail of the hippocampus of schizophrenics is flattened in comparison to the stronger bending of the tail in controls. A smaller effect is found in the hippocampal head at the hippocampal-amygdala transition region, confirming recent shape findings by Csernansky [2] . The Radius analysis shows that locations at the head and tail of the object, not the center, present differences. Differences between patients and controls in hippocampal radius asymmetry decrease over time. This reduction in group difference (of L/R difference) seems more pronounced in the Atypical group. The Atypical treated patients start (at an early age) less far from the Controls than do Typical treated, which might be interpreted as treatment effect or a clinical selection bias. Following this exploratory study, we will continue with an confirmatory analysis in an independent schizophrenia study where all hypothesis would be specified and fixed a priory before data would be collected.
5. Reduction to a model with a common slope for Drug − T ype x Age (equivalent to the simple interaction of Drug (yes, no) and Age). The test of Row x Col x Drug x Age gave a smaller p-value in this model (p-value = 0.0113).
A test of a equality of intercepts (difference in Drug − T ypes, typical versus atypical) was found to give p>.05. 6. Final reduction of the between subject model, including Age, Drug (yes, no),
and Age x Drug as predictors. The test of Row x Col x Drug x Age in the final model led to p = 0.0097 (Geisser-Greenhouse test). 7. The Row x Column shape was judged to be a quadratic (Row) by quadratic (Column) predicted surface (step-down interaction trend test).
